Cargando…
The Exciting New Field of HER2-Low Breast Cancer Treatment
SIMPLE SUMMARY: Breast cancer can express, at varied levels, a protein named HER2, commonly responsible for making it grow and send distant metastases. In the past, patients affected by the so called HER2-positive breast cancer had lower probabilities of cure and survival, though with the advent of...
Autores principales: | Eiger, Daniel, Agostinetto, Elisa, Saúde-Conde, Rita, de Azambuja, Evandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957750/ https://www.ncbi.nlm.nih.gov/pubmed/33804398 http://dx.doi.org/10.3390/cancers13051015 |
Ejemplares similares
-
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023) -
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience
por: Franzoi, Maria Alice, et al.
Publicado: (2021) -
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021) -
Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer
por: Eiger, Daniel, et al.
Publicado: (2020) -
CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)